An interventional study of Provider nudge and Patient nudge in Hypertension and Primary Care, sponsored by Brigham and Women's Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Hypertension by Brigham and Women's Hospital — 6 open to participants now, 10 under way, none of them phase 3. Hypertension · Brigham and Women's Hospital.
Among the 53 studies in Hypertension by Brigham and Women's Hospital, this one is the 11th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2026, is one of 29 with no phase, and was the 51st registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →6 of the 53 studies in Hypertension by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18–75
Brigham and Women's Hospital · Sites in United States
Ages 18–85
Brigham and Women's Hospital · Sites in United States
Ages 35+
Brigham and Women's Hospital · Sites in United States
Ages 18–50
Brigham and Women's Hospital
Ages 65+ · Healthy volunteers
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 1983; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 720 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 130 across the 40 interventional studies, 40,048 across the 11 observational. Of the 34 that completed or were terminated, 19 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
5 of the studies in Hypertension by Brigham and Women's Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05593055Brigham and Women's HospitalMineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension | 2027-04-01 |
| NCT07228065Brigham and Women's HospitalFixed-Dose Combinations Pragmatic Randomized Implementation Trial for Blood Pressure Control | 2027-04-30 |
| NCT07869966Brigham and Women's HospitalAntihypertensive Self-titration in US Primary Care | 2027-08 |
| NCT01426529Brigham and Women's HospitalCaveolin-1 and Vascular Dysfunction | 2027-10-15 |
| NCT05030545Brigham and Women's HospitalCardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 53 studies in Hypertension by Brigham and Women's Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The proposed study is an effectiveness-implementation hybrid type II trial designed to evaluate the impact of provider- and patient-directed interventions on FDC use. The trial will test the effectiveness of theory-driven nudges tailored to address provider and patient barriers. All interventions will be pharmacist-driven, with pharmacists delivering information via nudges to providers and via nudges or more intensive interventions (i.e., CPA) to patients. Data to evaluate outcomes will be extracted from electronic health records.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pharmacists will deliver targeted nudges to providers through clinical decision support integrated into the EHR.
Behavioral: Provider nudge
In addition to provider nudges (Provider nudge only arm), patients will receive pharmacist delivered nudges (e.g., text messages) 1-7 days before the visit to encourage fixed dose combination medications.
Behavioral: Provider nudge · Behavioral: Patient nudge
In addition to provider nudges (Provider nudge only arm), patients will receive pharmacist counseling and prescribing delivered via virtual encounters after the visit.
Behavioral: Provider nudge · Behavioral: Pharmacist Virtual Visit
Pharmacists will deliver targeted nudges to providers through clinical decision support integrated into the electronic health record (EHR)
Patients will receive pharmacist-delivered nudges (e.g., text messages) 1-7 days before their visit to encourage fixed-dosed combinations
Patients will receive pharmacist counseling and prescribing delivered via virtual encounters after their visit
Change in systolic blood pressure
Data for this outcome will be extracted from electronic health records. The primary effectiveness outcome will be a change in ambulatory systolic blood pressure at 3 months. For patients who do not return within 3 months, their index visit reading will be carried forward.
Time frame: 6 months
Change in diastolic blood pressure
Change in diastolic blood pressure from qualifying visit blood pressure reading to the end of the 6-month follow-up, using EHR data
Time frame: 6 months
Percentage of patients with well-controlled blood pressure
Percentage of patients who reach blood pressure control defined as \<140/90mmHg
Time frame: 6 months
PCP level adoption: FDC prescribing; FDC discussion in EHR notes
Percentage of patients whose PCPs prescribe FDC within 6 months; any intensification at 6 months will also be explored; any FDC documentation in the notes
Time frame: 6 months
Patient level adoption: FDC adherence (fill)
Percentage of patients who fill their first FDC prescription within 6 months; filling any intensified prescription within 6 months will also be explored.
Time frame: 6 months
Started Aug 2026 (actual). Primary completion is estimated for Apr 2027, 8 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 8 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brigham and Women's Hospital →